

# Giant Cell Arteritis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/G21F9B8726EAEN.html>

Date: May 2024

Pages: 139

Price: US\$ 6,499.00 (Single User License)

ID: G21F9B8726EAEN

## Abstracts

The 7 major giant cell arteritis markets reached a value of US\$ 1,130.1 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 1,825.2 Million by 2034, exhibiting a growth rate (CAGR) of 4.45% during 2024-2034.

The giant cell arteritis market has been comprehensively analyzed in IMARC's new report titled "Giant Cell Arteritis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Giant cell arteritis, also known as temporal arteritis, refers to a type of systemic vasculitis that affects medium- to large-sized arteries, most commonly the temporal arteries that run along the sides of the head. The ailment causes inflammation and damage to the walls of the arteries, leading to narrowing or blockage of blood flow. The symptoms can vary widely but generally include severe headaches, scalp tenderness, jaw pain when chewing, fatigue, fever, weight loss, muscle aches, etc. In some cases, the disease can cause permanent vision loss due to damage to the ophthalmic artery, which supplies blood to the optic nerve. The diagnosis of the condition typically involves a combination of clinical evaluation, blood tests, and imaging procedures. A doctor will often start by taking a detailed medical history and performing a physical exam, looking for signs of inflammation, such as tenderness over the temporal arteries. Several blood tests are used to measure markers of inflammation, including erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP). Additionally, an ultrasound or angiography may be performed to assess the affected arteries and check for signs of blockages.

The rising prevalence of autoimmune disorders, in which the body's immune system targets healthy tissues and causes inflammation in the blood vessels, is primarily driving the giant cell arteritis market. In addition to this, the increasing incidence of several

potential risk factors, including respiratory infections, advancing age, inflammatory diseases like polymyalgia rheumatica, etc., is also bolstering the market growth. Furthermore, the widespread adoption of low-dose aspirin in combination with immunosuppressive drugs for reducing the likelihood of blood clot formation and other complications in patients is acting as another significant growth-inducing factor. Besides this, the emerging popularity of biologic therapies, such as tocilizumab, anakinra, abatacept, etc., to target specific components of the immune system involved in the inflammatory process is further creating a positive outlook for the market. Additionally, the escalating utilization of corticosteroid-sparing strategies on account of their several associated benefits, including minimal side effects, enhanced disease control, and a reduced risk of relapse, is also propelling the market growth. Moreover, the introduction of novel image-guided biopsies, such as ultrasound-guided temporal artery biopsy, which has improved the accuracy of diagnosis and lowered the need for invasive surgical biopsy procedures, is expected to drive the giant cell arteritis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the giant cell arteritis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for giant cell arteritis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the giant cell arteritis market in any manner.

#### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

#### Countries Covered

United States

Germany  
France  
United Kingdom  
Italy  
Spain  
Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario  
Historical, current, and future performance of the giant cell arteritis market  
Historical, current, and future performance of various therapeutic categories in the market  
Sales of various drugs across the giant cell arteritis market  
Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current giant cell arteritis marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview  
Mechanism of Action  
Regulatory Status  
Clinical Trial Results  
Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview  
Mechanism of Action  
Regulatory Status  
Clinical Trial Results  
Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

## Key Questions Answered in this Report: Market Insights

How has the giant cell arteritis market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the giant cell arteritis market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the giant cell arteritis market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

## Epidemiology Insights

What is the number of prevalent cases (?2018-2034?) of giant cell arteritis across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of giant cell arteritis by age across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of giant cell arteritis by gender across the seven major markets?

How many patients are diagnosed (?2018-2034?) with giant cell arteritis across the seven major markets?

What is the size of the giant cell arteritis patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of giant cell arteritis?

What will be the growth rate of patients across the seven major markets?

## Giant Cell Arteritis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for giant cell arteritis drugs across the seven

major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the giant cell arteritis market?

What are the key regulatory events related to the giant cell arteritis market?

What is the structure of clinical trial landscape by status related to the giant cell arteritis market?

What is the structure of clinical trial landscape by phase related to the giant cell arteritis market?

What is the structure of clinical trial landscape by route of administration related to the giant cell arteritis market?

## Contents

### **1 PREFACE**

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 GIANT CELL ARTERITIS - INTRODUCTION**

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (?2018-2023?) and Forecast (?2024-2034?)
- 4.5 Competitive Intelligence

### **5 GIANT CELL ARTERITIS - DISEASE OVERVIEW**

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 GIANT CELL ARTERITIS - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (?2018-2023?)
  - 7.2.2 Epidemiology Forecast (?2024-2034?)
  - 7.2.3 Epidemiology by Age (?2018-2034?)
  - 7.2.4 Epidemiology by Gender (?2018-2034?)
  - 7.2.5 Diagnosed Cases (?2018-2034?)
  - 7.2.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (?2018-2023?)
  - 7.3.2 Epidemiology Forecast (?2024-2034?)
  - 7.3.3 Epidemiology by Age (?2018-2034?)
  - 7.3.4 Epidemiology by Gender (?2018-2034?)
  - 7.3.5 Diagnosed Cases (?2018-2034?)
  - 7.3.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (?2018-2023?)
  - 7.4.2 Epidemiology Forecast (?2024-2034?)
  - 7.4.3 Epidemiology by Age (?2018-2034?)
  - 7.4.4 Epidemiology by Gender (?2018-2034?)
  - 7.4.5 Diagnosed Cases (?2018-2034?)
  - 7.4.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (?2018-2023?)
  - 7.5.2 Epidemiology Forecast (?2024-2034?)
  - 7.5.3 Epidemiology by Age (?2018-2034?)
  - 7.5.4 Epidemiology by Gender (?2018-2034?)
  - 7.5.5 Diagnosed Cases (?2018-2034?)
  - 7.5.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (?2018-2023?)
  - 7.6.2 Epidemiology Forecast (?2024-2034?)
  - 7.6.3 Epidemiology by Age (?2018-2034?)
  - 7.6.4 Epidemiology by Gender (?2018-2034?)
  - 7.6.5 Diagnosed Cases (?2018-2034?)
  - 7.6.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (?2018-2023?)
  - 7.7.2 Epidemiology Forecast (?2024-2034?)
  - 7.7.3 Epidemiology by Age (?2018-2034?)

- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (?2018-2023?)
  - 7.8.2 Epidemiology Forecast (?2024-2034?)
  - 7.8.3 Epidemiology by Age (?2018-2034?)
  - 7.8.4 Epidemiology by Gender (?2018-2034?)
  - 7.8.5 Diagnosed Cases (?2018-2034?)
  - 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (?2018-2023?)
  - 7.9.2 Epidemiology Forecast (?2024-2034?)
  - 7.9.3 Epidemiology by Age (?2018-2034?)
  - 7.9.4 Epidemiology by Gender (?2018-2034?)
  - 7.9.5 Diagnosed Cases (?2018-2034?)
  - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

## **8 GIANT CELL ARTERITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 GIANT CELL ARTERITIS - UNMET NEEDS**

## **10 GIANT CELL ARTERITIS - KEY ENDPOINTS OF TREATMENT**

## **11 GIANT CELL ARTERITIS - MARKETED PRODUCTS**

- 11.1 List of Giant Cell Arteritis Marketed Drugs Across the Top 7 Markets
  - 11.1.1 Actemra (Tocilizumab) - Chugai Pharmaceutical/Roche
    - 11.1.1.1 Drug Overview
    - 11.1.1.2 Mechanism of Action
    - 11.1.1.3 Regulatory Status
    - 11.1.1.4 Clinical Trial Results
    - 11.1.1.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.



## **12 GIANT CELL ARTERITIS - PIPELINE DRUGS**

### 12.1 List of Giant Cell Arteritis Pipeline Drugs Across the Top 7 Markets

#### 12.1.1 KPL 301 - CSL/Kiniksa Pharmaceuticals

- 12.1.1.1 Drug Overview
- 12.1.1.2 Mechanism of Action
- 12.1.1.3 Clinical Trial Results
- 12.1.1.4 Safety and Efficacy
- 12.1.1.5 Regulatory Status

#### 12.1.2 Secukinumab - Novartis

- 12.1.2.1 Drug Overview
- 12.1.2.2 Mechanism of Action
- 12.1.2.3 Clinical Trial Results
- 12.1.2.4 Safety and Efficacy
- 12.1.2.5 Regulatory Status

#### 12.1.3 Guselkumab - Janssen Biotech

- 12.1.3.1 Drug Overview
- 12.1.3.2 Mechanism of Action
- 12.1.3.3 Clinical Trial Results
- 12.1.3.4 Safety and Efficacy
- 12.1.3.5 Regulatory Status

#### 12.1.4 Upadacitinib - AbbVie

- 12.1.4.1 Drug Overview
- 12.1.4.2 Mechanism of Action
- 12.1.4.3 Clinical Trial Results
- 12.1.4.4 Safety and Efficacy
- 12.1.4.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

## **13. GIANT CELL ARTERITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

## **14. GIANT CELL ARTERITIS – CLINICAL TRIAL LANDSCAPE**

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration

## 14.4 Key Regulatory Events

# 15 GIANT CELL ARTERITIS - MARKET SCENARIO

## 15.1 Market Scenario - Key Insights

## 15.2 Market Scenario - Top 7 Markets

### 15.2.1 Giant Cell Arteritis - Market Size

#### 15.2.1.1 Market Size (?2018-2023?)

#### 15.2.1.2 Market Forecast (?2024-2034?)

### 15.2.2 Giant Cell Arteritis - Market Size by Therapies

#### 15.2.2.1 Market Size by Therapies (?2018-2023?)

#### 15.2.2.2 Market Forecast by Therapies (?2024-2034?)

## 15.3 Market Scenario - United States

### 15.3.1 Giant Cell Arteritis - Market Size

#### 15.3.1.1 Market Size (?2018-2023?)

#### 15.3.1.2 Market Forecast (?2024-2034?)

### 15.3.2 Giant Cell Arteritis - Market Size by Therapies

#### 15.3.2.1 Market Size by Therapies (?2018-2023?)

#### 15.3.2.2 Market Forecast by Therapies (?2024-2034?)

### 15.3.3 Giant Cell Arteritis - Access and Reimbursement Overview

## 15.4 Market Scenario - Germany

### 15.4.1 Giant Cell Arteritis - Market Size

#### 15.4.1.1 Market Size (?2018-2023?)

#### 15.4.1.2 Market Forecast (?2024-2034?)

### 15.4.2 Giant Cell Arteritis - Market Size by Therapies

#### 15.4.2.1 Market Size by Therapies (?2018-2023?)

#### 15.4.2.2 Market Forecast by Therapies (?2024-2034?)

### 15.4.3 Giant Cell Arteritis - Access and Reimbursement Overview

## 15.5 Market Scenario - France

### 15.5.1 Giant Cell Arteritis - Market Size

#### 15.5.1.1 Market Size (?2018-2023?)

#### 15.5.1.2 Market Forecast (?2024-2034?)

### 15.5.2 Giant Cell Arteritis - Market Size by Therapies

#### 15.5.2.1 Market Size by Therapies (?2018-2023?)

#### 15.5.2.2 Market Forecast by Therapies (?2024-2034?)

### 15.5.3 Giant Cell Arteritis - Access and Reimbursement Overview

## 15.6 Market Scenario - United Kingdom

### 15.6.1 Giant Cell Arteritis - Market Size

#### 15.6.1.1 Market Size (?2018-2023?)

- 15.6.1.2 Market Forecast (?2024-2034?)
- 15.6.2 Giant Cell Arteritis - Market Size by Therapies
  - 15.6.2.1 Market Size by Therapies (?2018-2023?)
  - 15.6.2.2 Market Forecast by Therapies (?2024-2034?)
- 15.6.3 Giant Cell Arteritis - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Giant Cell Arteritis - Market Size
    - 15.7.1.1 Market Size (?2018-2023?)
    - 15.7.1.2 Market Forecast (?2024-2034?)
  - 15.7.2 Giant Cell Arteritis - Market Size by Therapies
    - 15.7.2.1 Market Size by Therapies (?2018-2023?)
    - 15.7.2.2 Market Forecast by Therapies (?2024-2034?)
  - 15.7.3 Giant Cell Arteritis - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
  - 15.8.1 Giant Cell Arteritis - Market Size
    - 15.8.1.1 Market Size (?2018-2023?)
    - 15.8.1.2 Market Forecast (?2024-2034?)
  - 15.8.2 Giant Cell Arteritis - Market Size by Therapies
    - 15.8.2.1 Market Size by Therapies (?2018-2023?)
    - 15.8.2.2 Market Forecast by Therapies (?2024-2034?)
  - 15.8.3 Giant Cell Arteritis - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Giant Cell Arteritis - Market Size
    - 15.9.1.1 Market Size (?2018-2023?)
    - 15.9.1.2 Market Forecast (?2024-2034?)
  - 15.9.2 Giant Cell Arteritis - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (?2018-2023?)
    - 15.9.2.2 Market Forecast by Therapies (?2024-2034?)
  - 15.9.3 Giant Cell Arteritis - Access and Reimbursement Overview

## **16 GIANT CELL ARTERITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 GIANT CELL ARTERITIS MARKET - SWOT ANALYSIS**

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

## **18 GIANT CELL ARTERITIS MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Giant Cell Arteritis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/G21F9B8726EAEN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G21F9B8726EAEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

